Criteria to select molecular targets for anti-fibrotic therapy

Area of Science:

• Rheumatology and Immunology
• Fibrosis Research
• Translational Medicine

Background:

• Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by widespread tissue fibrosis, leading to significant morbidity and mortality.
• Developing effective anti-fibrotic therapies for SSc is a critical unmet need, yet patient numbers for clinical trials are limited.
• Identifying promising molecular targets is essential for advancing SSc treatment.

Framework:

• This article proposes consensus-based criteria for selecting molecular targets for anti-fibrotic therapies in SSc clinical trials.
• Key criteria include strong experimental evidence of fibrosis inhibition (ideally in multiple SSc animal models), clinical availability of inhibitors, and existing clinical safety data from other diseases.
• Availability of funding for SSc clinical trials is also a crucial factor.

Implementation:

• The proposed framework aims to streamline the selection process for novel anti-fibrotic drug candidates.
• Prioritizing targets based on these criteria can accelerate the translation of preclinical findings into clinical studies.
• This approach helps optimize resource allocation for SSc drug development.

Implications:

• Implementing these criteria can enhance the efficiency and success rate of clinical trials for SSc fibrosis.
• This strategic selection process may lead to faster development of much-needed treatments for SSc patients.
• The framework provides a standardized approach for prioritizing therapeutic targets in rare fibrotic diseases.